Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United Laboratories International HoldingsSTU:UNJ 65 Operating Margin % is 2.08% as of Dec. 2025, which is 86% below its 10-year median of 15.06. GuruFocus rates STU:UNJ with a GF Score™ of 65/100 and a GF Value™ of €0.93 (Fairly Valued). The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, United Laboratories International Holdings ranks better than 79.29% on this metric.
United Laboratories International Holdings (STU:UNJ) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
United Laboratories International Holdings Operating Margin % Related Terms
United Laboratories International Holdings Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings Operating Margin % Chart
United Laboratories International Holdings Annual Data
STU:UNJ vs ZTS, UTHR: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Laboratories International Holdings Operating Margin % vs Drug Manufacturers Industry
United Laboratories International Holdings Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings (STU:UNJ) has a Operating Margin % of 2.08% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on United Laboratories International Holdings and its competitors. This is 86% below median its historical median of 15.06. Over the past decade, United Laboratories International Holdings' Operating Margin % has ranged from 7.97 to 23.94. According to the industry distribution chart, United Laboratories International Holdings ranks #199 out of 961 companies in the Drug Manufacturers industry, placing it in the top 20.7%.
Is United Laboratories International Holdings' Operating Margin % too high?
United Laboratories International Holdings' current Operating Margin % of 2.08% is 86% below median its 10-year median of 15.06. Over the past 10 years, this metric has ranged from a low of 7.97 to a high of 23.94. The Drug Manufacturers industry median Operating Margin % is 7.57. United Laboratories International Holdings' value of 2.08% is 72.5% below this industry median. Based on the distribution chart, United Laboratories International Holdings ranks #199 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Laboratories International Holdings has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does United Laboratories International Holdings' Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, United Laboratories International Holdings ranks #199 out of 961 companies for Operating Margin %. This places United Laboratories International Holdings in the top 21% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.57. United Laboratories International Holdings' value of 2.08% is 72.5% below this benchmark. Historically, United Laboratories International Holdings' own Operating Margin % has ranged from 7.97 to 23.94 over the past decade. While the company's 10-year median is 15.06 vs. the industry median of 7.57, United Laboratories International Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.57, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Laboratories International Holdings's current Operating Margin % of 2.08% is 72.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on United Laboratories International Holdings and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Laboratories International Holdings's current Operating Margin % is 2.08%, which is 86% below median its own 10-year median of 15.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Laboratories International Holdings stock overvalued right now?
Based on GuruFocus' analysis, United Laboratories International Holdings (STU:UNJ) is currently considered Fairly Valued. The stock's GF Value™ is €0.93, compared to a current price of €1.00 — trading 7% above its estimated fair value. The current Operating Margin % is 2.08%, which is 86% below median its 10-year median of 15.06 and 72.5% below the Drug Manufacturers industry median of 7.57. United Laboratories International Holdings' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For United Laboratories International Holdings (STU:UNJ), the current Operating Margin % is 2.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Laboratories International Holdings (STU:UNJ) Overvalued in 2026?
Based on GuruFocus' analysis, United Laboratories International Holdings stock appears to be overvalued.
The current stock price of €1.00 is trading 7% above its estimated GF Value™ of €0.93.
GuruFocus considers United Laboratories International Holdings to be Fairly Valued.
Key valuation signals for STU:UNJ:
Operating Margin %: 2.08% (86% below median its 10-year median of 15.06)
GF Value™: €0.93 vs. price of €1.00 (7% above fair value)
Industry Position: 72.5% below the Drug Manufacturers median (#199 of 961)
No single metric tells the full story. See the STU:UNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Laboratories International Holdings Business Description
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Finished products segment, followed by Bulk medicine. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
65GF Score
Get the complete analysis for STU:UNJ
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:UNJ has been successfully added to your 
